APO Research
Talk to an analyst

APO RESEARCH · REPORT

Second-Generation Antipsychotics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Second-Generation Antipsychotics Market Outlook and Growth Opportunities 2026

23 December 2025200 pages

Choose your research edition.

Industry ResearchSecond-Generation Antipsychotics Industry Research Report 2026148 pages · $2,950 USDIndustry Growth & TrendsGlobal Second-Generation Antipsychotics Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Second-Generation Antipsychotics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Second-Generation Antipsychotics Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Second-Generation Antipsychotics Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Second-Generation Antipsychotics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Second-Generation Antipsychotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Second-Generation Antipsychotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Second-Generation Antipsychotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Second-Generation Antipsychotics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Second-Generation Antipsychotics market include Chia Tai Tianqing Pharmaceutical, Yangtze River Pharmaceutical Group, CSPC Pharmaceutical Group, Qilu Pharmaceutical, Novartis, Merck, Luye Pharma Group, Roche and Livzon Pharmaceutical Group, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Second-Generation Antipsychotics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Second-Generation Antipsychotics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Second-Generation Antipsychotics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Second-Generation Antipsychotics market size, projected growth trends, production technologies, key applications, and end-use industries.

Second-Generation Antipsychotics Segment by Company

Chia Tai Tianqing Pharmaceutical

Yangtze River Pharmaceutical Group

CSPC Pharmaceutical Group

Qilu Pharmaceutical

Novartis

Merck

Luye Pharma Group

Roche

Livzon Pharmaceutical Group

Eli Lilly

Chengdu Kanghong Pharmaceutical

Pfizer

Hansoh Pharma

Hisun Pharmaceutical

Nhwa Pharmaceutical

AbbVie

Sumitomo Dainippon Pharma

Otsuka Pharmaceutical

Johnson And Johnson

Ipsen

Second-Generation Antipsychotics Segment by Type

Selective Dopamine Receptor Antagonists

Multi Receptor Acting Drugs

Dopamine Receptor Partial Agonists

5-Hydroxytryptamine And Dopamine Receptor Antagonists

Second-Generation Antipsychotics Segment by Application

Adjuvant Treatment For Depression

Bipolar Disorder

Schizophrenia

Other Mental Illnesses

Second-Generation Antipsychotics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Second-Generation Antipsychotics status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Second-Generation Antipsychotics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Second-Generation Antipsychotics significant trends, drivers, influence factors in global and regions.

6. To analyze Second-Generation Antipsychotics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Second-Generation Antipsychotics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Second-Generation Antipsychotics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Second-Generation Antipsychotics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Second-Generation Antipsychotics market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Second-Generation Antipsychotics industry.

Chapter 3: Detailed analysis of Second-Generation Antipsychotics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Second-Generation Antipsychotics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Second-Generation Antipsychotics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Second-Generation Antipsychotics Industry Trends Table 2. Second-Generation Antipsychotics Industry Drivers Table 3. Second-Generation Antipsychotics Industry Opportunities and Challenges Table 4. Second-Generation Antipsychotics Industry Restraints Table 5. Global Second-Generation Antipsychotics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Second-Generation Antipsychotics Revenue Share by Company (2021-2026) Table 7. Global Second-Generation Antipsychotics Sales Volume by Company (units) & (2021-2026) Table 8. Global Second-Generation Antipsychotics Sales Volume Share by Company (2021-2026) Table 9. Global Second-Generation Antipsychotics Average Price (USD/unit) of Company (2021-2026) Table 10. Global Second-Generation Antipsychotics Company Ranking, (2024-2026) & (USD Million) Table 11. Global Second-Generation Antipsychotics Key Company Manufacturing Base & Headquarters Table 12. Global Second-Generation Antipsychotics Company, Product Type & Application Table 13. Global Second-Generation Antipsychotics Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Second-Generation Antipsychotics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Selective Dopamine Receptor Antagonists Table 18. Significant Companies of Multi Receptor Acting Drugs Table 19. Significant Companies of Dopamine Receptor Partial Agonists Table 20. Significant Companies of 5-Hydroxytryptamine And Dopamine Receptor Antagonists Table 21. Global Second-Generation Antipsychotics Sales Volume by Type 2021 VS 2025 VS 2032 (units) Table 22. Global Second-Generation Antipsychotics Sales Volume by Type (2021-2026) & (units) Table 23. Global Second-Generation Antipsychotics Sales Volume by Type (2027-2032) & (units) Table 24. Global Second-Generation Antipsychotics Sales Volume Share by Type (2021-2026) Table 25. Global Second-Generation Antipsychotics Sales Volume Share by Type (2027-2032) Table 26. Global Second-Generation Antipsychotics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Second-Generation Antipsychotics Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Second-Generation Antipsychotics Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Second-Generation Antipsychotics Sales Value Share by Type (2021-2026) Table 30. Global Second-Generation Antipsychotics Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Adjuvant Treatment For Depression Table 32. Significant Companies of Bipolar Disorder Table 33. Significant Companies of Schizophrenia Table 34. Significant Companies of Other Mental Illnesses Table 35. Global Second-Generation Antipsychotics Sales Volume by Application 2021 VS 2025 VS 2032 (units) Table 36. Global Second-Generation Antipsychotics Sales Volume by Application (2021-2026) & (units) Table 37. Global Second-Generation Antipsychotics Sales Volume by Application (2027-2032) & (units) Table 38. Global Second-Generation Antipsychotics Sales Volume Share by Application (2021-2026) Table 39. Global Second-Generation Antipsychotics Sales Volume Share by Application (2027-2032) Table 40. Global Second-Generation Antipsychotics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Second-Generation Antipsychotics Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Second-Generation Antipsychotics Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Second-Generation Antipsychotics Sales Value Share by Application (2021-2026) Table 44. Global Second-Generation Antipsychotics Sales Value Share by Application (2027-2032) Table 45. Global Second-Generation Antipsychotics Sales by Region: 2021 VS 2025 VS 2032 (units) Table 46. Global Second-Generation Antipsychotics Sales by Region (2021-2026) & (units) Table 47. Global Second-Generation Antipsychotics Sales Market Share by Region (2021-2026) Table 48. Global Second-Generation Antipsychotics Sales by Region (2027-2032) & (units) Table 49. Global Second-Generation Antipsychotics Sales Market Share by Region (2027-2032) Table 50. Global Second-Generation Antipsychotics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Second-Generation Antipsychotics Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Second-Generation Antipsychotics Sales Value Share by Region (2021-2026) Table 53. Global Second-Generation Antipsychotics Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Second-Generation Antipsychotics Sales Value Share by Region (2027-2032) Table 55. Global Second-Generation Antipsychotics Market Average Price (USD/unit) by Region (2021-2026) Table 56. Global Second-Generation Antipsychotics Market Average Price (USD/unit) by Region (2027-2032) Table 57. Global Second-Generation Antipsychotics Sales by Country: 2021 VS 2025 VS 2032 (units) Table 58. Global Second-Generation Antipsychotics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Second-Generation Antipsychotics Sales by Country (2021-2026) & (units) Table 60. Global Second-Generation Antipsychotics Sales Market Share by Country (2021-2026) Table 61. Global Second-Generation Antipsychotics Sales by Country (2027-2032) & (units) Table 62. Global Second-Generation Antipsychotics Sales Market Share by Country (2027-2032) Table 63. Global Second-Generation Antipsychotics Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Second-Generation Antipsychotics Sales Value Market Share by Country (2021-2026) Table 65. Global Second-Generation Antipsychotics Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Second-Generation Antipsychotics Sales Value Market Share by Country (2027-2032) Table 67. Chia Tai Tianqing Pharmaceutical Company Information Table 68. Chia Tai Tianqing Pharmaceutical Business Overview Table 69. Chia Tai Tianqing Pharmaceutical Second-Generation Antipsychotics Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 70. Chia Tai Tianqing Pharmaceutical Second-Generation Antipsychotics Product Portfolio Table 71. Chia Tai Tianqing Pharmaceutical Recent Development Table 72. Yangtze River Pharmaceutical Group Company Information Table 73. Yangtze River Pharmaceutical Group Business Overview Table 74. Yangtze River Pharmaceutical Group Second-Generation Antipsychotics Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 75. Yangtze River Pharmaceutical Group Second-Generation Antipsychotics Product Portfolio Table 76. Yangtze River Pharmaceutical Group Recent Development Table 77. CSPC Pharmaceutical Group Company Information Table 78. CSPC Pharmaceutical Group Business Overview Table 79. CSPC Pharmaceutical Group Second-Generation Antipsychotics Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 80. CSPC Pharmaceutical Group Second-Generation Antipsychotics Product Portfolio Table 81. CSPC Pharmaceutical Group Recent Development Table 82. Qilu Pharmaceutical Company Information Table 83. Qilu Pharmaceutical Business Overview Table 84. Qilu Pharmaceutical Second-Generation Antipsychotics Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 85. Qilu Pharmaceutical Second-Generation Antipsychotics Product Portfolio Table 86. Qilu Pharmaceutical Recent Development Table 87. Novartis Company Information Table 88. Novartis Business Overview Table 89. Novartis Second-Generation Antipsychotics Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. Novartis Second-Generation Antipsychotics Product Portfolio Table 91. Novartis Recent Development Table 92. Merck Company Information Table 93. Merck Business Overview Table 94. Merck Second-Generation Antipsychotics Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. Merck Second-Generation Antipsychotics Product Portfolio Table 96. Merck Recent Development Table 97. Luye Pharma Group Company Information Table 98. Luye Pharma Group Business Overview Table 99. Luye Pharma Group Second-Generation Antipsychotics Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. Luye Pharma Group Second-Generation Antipsychotics Product Portfolio Table 101. Luye Pharma Group Recent Development Table 102. Roche Company Information Table 103. Roche Business Overview Table 104. Roche Second-Generation Antipsychotics Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. Roche Second-Generation Antipsychotics Product Portfolio Table 106. Roche Recent Development Table 107. Livzon Pharmaceutical Group Company Information Table 108. Livzon Pharmaceutical Group Business Overview Table 109. Livzon Pharmaceutical Group Second-Generation Antipsychotics Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. Livzon Pharmaceutical Group Second-Generation Antipsychotics Product Portfolio Table 111. Livzon Pharmaceutical Group Recent Development Table 112. Eli Lilly Company Information Table 113. Eli Lilly Business Overview Table 114. Eli Lilly Second-Generation Antipsychotics Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 115. Eli Lilly Second-Generation Antipsychotics Product Portfolio Table 116. Eli Lilly Recent Development Table 117. Chengdu Kanghong Pharmaceutical Company Information Table 118. Chengdu Kanghong Pharmaceutical Business Overview Table 119. Chengdu Kanghong Pharmaceutical Second-Generation Antipsychotics Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 120. Chengdu Kanghong Pharmaceutical Second-Generation Antipsychotics Product Portfolio Table 121. Chengdu Kanghong Pharmaceutical Recent Development Table 122. Pfizer Company Information Table 123. Pfizer Business Overview Table 124. Pfizer Second-Generation Antipsychotics Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 125. Pfizer Second-Generation Antipsychotics Product Portfolio Table 126. Pfizer Recent Development Table 127. Hansoh Pharma Company Information Table 128. Hansoh Pharma Business Overview Table 129. Hansoh Pharma Second-Generation Antipsychotics Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 130. Hansoh Pharma Second-Generation Antipsychotics Product Portfolio Table 131. Hansoh Pharma Recent Development Table 132. Hisun Pharmaceutical Company Information Table 133. Hisun Pharmaceutical Business Overview Table 134. Hisun Pharmaceutical Second-Generation Antipsychotics Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 135. Hisun Pharmaceutical Second-Generation Antipsychotics Product Portfolio Table 136. Hisun Pharmaceutical Recent Development Table 137. Nhwa Pharmaceutical Company Information Table 138. Nhwa Pharmaceutical Business Overview Table 139. Nhwa Pharmaceutical Second-Generation Antipsychotics Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 140. Nhwa Pharmaceutical Second-Generation Antipsychotics Product Portfolio Table 141. Nhwa Pharmaceutical Recent Development Table 142. AbbVie Company Information Table 143. AbbVie Business Overview Table 144. AbbVie Second-Generation Antipsychotics Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 145. AbbVie Second-Generation Antipsychotics Product Portfolio Table 146. AbbVie Recent Development Table 147. Sumitomo Dainippon Pharma Company Information Table 148. Sumitomo Dainippon Pharma Business Overview Table 149. Sumitomo Dainippon Pharma Second-Generation Antipsychotics Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 150. Sumitomo Dainippon Pharma Second-Generation Antipsychotics Product Portfolio Table 151. Sumitomo Dainippon Pharma Recent Development Table 152. Otsuka Pharmaceutical Company Information Table 153. Otsuka Pharmaceutical Business Overview Table 154. Otsuka Pharmaceutical Second-Generation Antipsychotics Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 155. Otsuka Pharmaceutical Second-Generation Antipsychotics Product Portfolio Table 156. Otsuka Pharmaceutical Recent Development Table 157. Johnson And Johnson Company Information Table 158. Johnson And Johnson Business Overview Table 159. Johnson And Johnson Second-Generation Antipsychotics Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 160. Johnson And Johnson Second-Generation Antipsychotics Product Portfolio Table 161. Johnson And Johnson Recent Development Table 162. Ipsen Company Information Table 163. Ipsen Business Overview Table 164. Ipsen Second-Generation Antipsychotics Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 165. Ipsen Second-Generation Antipsychotics Product Portfolio Table 166. Ipsen Recent Development Table 167. Key Raw Materials Table 168. Raw Materials Key Suppliers Table 169. Second-Generation Antipsychotics Distributors List Table 170. Second-Generation Antipsychotics Customers List Table 171. Research Programs/Design for This Report Table 172. Authors List of This Report Table 173. Secondary Sources Table 174. Primary Sources List of Figures Figure 1. Second-Generation Antipsychotics Product Image Figure 2. Global Second-Generation Antipsychotics Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Second-Generation Antipsychotics Sales Value (2021-2032) & (US$ Million) Figure 4. Global Second-Generation Antipsychotics Sales (2021-2032) & (units) Figure 5. Global Second-Generation Antipsychotics Sales Average Price (USD/unit) & (2021-2032) Figure 6. Global Second-Generation Antipsychotics Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Selective Dopamine Receptor Antagonists Image Figure 10. Multi Receptor Acting Drugs Image Figure 11. Dopamine Receptor Partial Agonists Image Figure 12. 5-Hydroxytryptamine And Dopamine Receptor Antagonists Image Figure 13. Global Second-Generation Antipsychotics Sales Volume by Type (2021 VS 2025 VS 2032) & (units) Figure 14. Global Second-Generation Antipsychotics Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Second-Generation Antipsychotics Sales Volume Share by Type (2021-2032) Figure 16. Global Second-Generation Antipsychotics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Second-Generation Antipsychotics Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Second-Generation Antipsychotics Sales Value Share by Type (2021-2032) Figure 19. Adjuvant Treatment For Depression Image Figure 20. Bipolar Disorder Image Figure 21. Schizophrenia Image Figure 22. Other Mental Illnesses Image Figure 23. Global Second-Generation Antipsychotics Sales Volume by Application (2021 VS 2025 VS 2032) & (units) Figure 24. Global Second-Generation Antipsychotics Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Second-Generation Antipsychotics Sales Volume Share by Application (2021-2032) Figure 26. Global Second-Generation Antipsychotics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Second-Generation Antipsychotics Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Second-Generation Antipsychotics Sales Value Share by Application (2021-2032) Figure 29. Global Second-Generation Antipsychotics Sales by Region: 2021 VS 2025 VS 2032 (units) Figure 30. Global Second-Generation Antipsychotics Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Second-Generation Antipsychotics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Second-Generation Antipsychotics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Second-Generation Antipsychotics Sales Value (2021-2032) & (US$ Million) Figure 34. North America Second-Generation Antipsychotics Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Second-Generation Antipsychotics Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Second-Generation Antipsychotics Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Second-Generation Antipsychotics Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Second-Generation Antipsychotics Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Second-Generation Antipsychotics Sales Value (2021-2032) & (US$ Million) Figure 40. South America Second-Generation Antipsychotics Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Second-Generation Antipsychotics Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Second-Generation Antipsychotics Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Second-Generation Antipsychotics Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Second-Generation Antipsychotics Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Selective Dopamine Receptor Antagonists
  • Multi Receptor Acting Drugs
  • Dopamine Receptor Partial Agonists
  • 5-Hydroxytryptamine And Dopamine Receptor Antagonists
Applications
  • Adjuvant Treatment For Depression
  • Bipolar Disorder
  • Schizophrenia
  • Other Mental Illnesses
Companies covered
  • Chia Tai Tianqing Pharmaceutical
  • Yangtze River Pharmaceutical Group
  • CSPC Pharmaceutical Group
  • Qilu Pharmaceutical
  • Novartis
  • Merck
  • Luye Pharma Group
  • Roche
  • Livzon Pharmaceutical Group
  • Eli Lilly
  • Chengdu Kanghong Pharmaceutical
  • Pfizer
  • Hansoh Pharma
  • Hisun Pharmaceutical
  • Nhwa Pharmaceutical
  • AbbVie
  • Sumitomo Dainippon Pharma
  • Otsuka Pharmaceutical
  • Johnson And Johnson
  • Ipsen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Second-Generation Antipsychotics Sales Value (2021-2032)
  4. 1.2.2 Global Second-Generation Antipsychotics Sales Volume (2021-2032)
  5. 1.2.3 Global Second-Generation Antipsychotics Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Second-Generation Antipsychotics Market Dynamics
  1. 2.1 Second-Generation Antipsychotics Industry Trends
  2. 2.2 Second-Generation Antipsychotics Industry Drivers
  3. 2.3 Second-Generation Antipsychotics Industry Opportunities and Challenges
  4. 2.4 Second-Generation Antipsychotics Industry Restraints
3 Second-Generation Antipsychotics Market by Company
  1. 3.1 Global Second-Generation Antipsychotics Company Revenue Ranking in 2025
  2. 3.2 Global Second-Generation Antipsychotics Revenue by Company (2021-2026)
  3. 3.3 Global Second-Generation Antipsychotics Sales Volume by Company (2021-2026)
  4. 3.4 Global Second-Generation Antipsychotics Average Price by Company (2021-2026)
  5. 3.5 Global Second-Generation Antipsychotics Company Ranking (2024-2026)
  6. 3.6 Global Second-Generation Antipsychotics Company Manufacturing Base and Headquarters
  7. 3.7 Global Second-Generation Antipsychotics Company Product Type and Application
  8. 3.8 Global Second-Generation Antipsychotics Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Second-Generation Antipsychotics Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Second-Generation Antipsychotics Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Second-Generation Antipsychotics Market by Type
  1. 4.1 Second-Generation Antipsychotics Type Introduction
  2. 4.1.1 Selective Dopamine Receptor Antagonists
  3. 4.1.2 Multi Receptor Acting Drugs
  4. 4.1.3 Dopamine Receptor Partial Agonists
  5. 4.1.4 5-Hydroxytryptamine And Dopamine Receptor Antagonists
  6. 4.2 Global Second-Generation Antipsychotics Sales Volume by Type
  7. 4.2.1 Global Second-Generation Antipsychotics Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Second-Generation Antipsychotics Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Second-Generation Antipsychotics Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Second-Generation Antipsychotics Sales Value by Type
  11. 4.3.1 Global Second-Generation Antipsychotics Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Second-Generation Antipsychotics Sales Value by Type (2021-2032)
  13. 4.3.3 Global Second-Generation Antipsychotics Sales Value Share by Type (2021-2032)
5 Second-Generation Antipsychotics Market by Application
  1. 5.1 Second-Generation Antipsychotics Application Introduction
  2. 5.1.1 Adjuvant Treatment For Depression
  3. 5.1.2 Bipolar Disorder
  4. 5.1.3 Schizophrenia
  5. 5.1.4 Other Mental Illnesses
  6. 5.2 Global Second-Generation Antipsychotics Sales Volume by Application
  7. 5.2.1 Global Second-Generation Antipsychotics Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Second-Generation Antipsychotics Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Second-Generation Antipsychotics Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Second-Generation Antipsychotics Sales Value by Application
  11. 5.3.1 Global Second-Generation Antipsychotics Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Second-Generation Antipsychotics Sales Value by Application (2021-2032)
  13. 5.3.3 Global Second-Generation Antipsychotics Sales Value Share by Application (2021-2032)
6 Second-Generation Antipsychotics Regional Sales and Value Analysis
  1. 6.1 Global Second-Generation Antipsychotics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Second-Generation Antipsychotics Sales by Region (2021-2032)
  3. 6.2.1 Global Second-Generation Antipsychotics Sales by Region: 2021-2026
  4. 6.2.2 Global Second-Generation Antipsychotics Sales by Region (2027-2032)
  5. 6.3 Global Second-Generation Antipsychotics Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Second-Generation Antipsychotics Sales Value by Region (2021-2032)
  7. 6.4.1 Global Second-Generation Antipsychotics Sales Value by Region: 2021-2026
  8. 6.4.2 Global Second-Generation Antipsychotics Sales Value by Region (2027-2032)
  9. 6.5 Global Second-Generation Antipsychotics Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Second-Generation Antipsychotics Sales Value (2021-2032)
  12. 6.6.2 North America Second-Generation Antipsychotics Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Second-Generation Antipsychotics Sales Value (2021-2032)
  15. 6.7.2 Europe Second-Generation Antipsychotics Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Second-Generation Antipsychotics Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Second-Generation Antipsychotics Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Second-Generation Antipsychotics Sales Value (2021-2032)
  21. 6.9.2 South America Second-Generation Antipsychotics Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Second-Generation Antipsychotics Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Second-Generation Antipsychotics Sales Value Share by Country, 2025 VS 2032
7 Second-Generation Antipsychotics Country-level Sales and Value Analysis
  1. 7.1 Global Second-Generation Antipsychotics Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Second-Generation Antipsychotics Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Second-Generation Antipsychotics Sales by Country (2021-2032)
  4. 7.3.1 Global Second-Generation Antipsychotics Sales by Country (2021-2026)
  5. 7.3.2 Global Second-Generation Antipsychotics Sales by Country (2027-2032)
  6. 7.4 Global Second-Generation Antipsychotics Sales Value by Country (2021-2032)
  7. 7.4.1 Global Second-Generation Antipsychotics Sales Value by Country (2021-2026)
  8. 7.4.2 Global Second-Generation Antipsychotics Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Second-Generation Antipsychotics Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Second-Generation Antipsychotics Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Second-Generation Antipsychotics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chia Tai Tianqing Pharmaceutical
  2. 8.1.1 Chia Tai Tianqing Pharmaceutical Company Information
  3. 8.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
  4. 8.1.3 Chia Tai Tianqing Pharmaceutical Second-Generation Antipsychotics Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Chia Tai Tianqing Pharmaceutical Second-Generation Antipsychotics Product Portfolio
  6. 8.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  7. 8.2 Yangtze River Pharmaceutical Group
  8. 8.2.1 Yangtze River Pharmaceutical Group Company Information
  9. 8.2.2 Yangtze River Pharmaceutical Group Business Overview
  10. 8.2.3 Yangtze River Pharmaceutical Group Second-Generation Antipsychotics Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Yangtze River Pharmaceutical Group Second-Generation Antipsychotics Product Portfolio
  12. 8.2.5 Yangtze River Pharmaceutical Group Recent Developments
  13. 8.3 CSPC Pharmaceutical Group
  14. 8.3.1 CSPC Pharmaceutical Group Company Information
  15. 8.3.2 CSPC Pharmaceutical Group Business Overview
  16. 8.3.3 CSPC Pharmaceutical Group Second-Generation Antipsychotics Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 CSPC Pharmaceutical Group Second-Generation Antipsychotics Product Portfolio
  18. 8.3.5 CSPC Pharmaceutical Group Recent Developments
  19. 8.4 Qilu Pharmaceutical
  20. 8.4.1 Qilu Pharmaceutical Company Information
  21. 8.4.2 Qilu Pharmaceutical Business Overview
  22. 8.4.3 Qilu Pharmaceutical Second-Generation Antipsychotics Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Qilu Pharmaceutical Second-Generation Antipsychotics Product Portfolio
  24. 8.4.5 Qilu Pharmaceutical Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Second-Generation Antipsychotics Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Second-Generation Antipsychotics Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Merck
  32. 8.6.1 Merck Company Information
  33. 8.6.2 Merck Business Overview
  34. 8.6.3 Merck Second-Generation Antipsychotics Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Merck Second-Generation Antipsychotics Product Portfolio
  36. 8.6.5 Merck Recent Developments
  37. 8.7 Luye Pharma Group
  38. 8.7.1 Luye Pharma Group Company Information
  39. 8.7.2 Luye Pharma Group Business Overview
  40. 8.7.3 Luye Pharma Group Second-Generation Antipsychotics Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Luye Pharma Group Second-Generation Antipsychotics Product Portfolio
  42. 8.7.5 Luye Pharma Group Recent Developments
  43. 8.8 Roche
  44. 8.8.1 Roche Company Information
  45. 8.8.2 Roche Business Overview
  46. 8.8.3 Roche Second-Generation Antipsychotics Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Roche Second-Generation Antipsychotics Product Portfolio
  48. 8.8.5 Roche Recent Developments
  49. 8.9 Livzon Pharmaceutical Group
  50. 8.9.1 Livzon Pharmaceutical Group Company Information
  51. 8.9.2 Livzon Pharmaceutical Group Business Overview
  52. 8.9.3 Livzon Pharmaceutical Group Second-Generation Antipsychotics Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Livzon Pharmaceutical Group Second-Generation Antipsychotics Product Portfolio
  54. 8.9.5 Livzon Pharmaceutical Group Recent Developments
  55. 8.10 Eli Lilly
  56. 8.10.1 Eli Lilly Company Information
  57. 8.10.2 Eli Lilly Business Overview
  58. 8.10.3 Eli Lilly Second-Generation Antipsychotics Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Eli Lilly Second-Generation Antipsychotics Product Portfolio
  60. 8.10.5 Eli Lilly Recent Developments
  61. 8.11 Chengdu Kanghong Pharmaceutical
  62. 8.11.1 Chengdu Kanghong Pharmaceutical Company Information
  63. 8.11.2 Chengdu Kanghong Pharmaceutical Business Overview
  64. 8.11.3 Chengdu Kanghong Pharmaceutical Second-Generation Antipsychotics Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Chengdu Kanghong Pharmaceutical Second-Generation Antipsychotics Product Portfolio
  66. 8.11.5 Chengdu Kanghong Pharmaceutical Recent Developments
  67. 8.12 Pfizer
  68. 8.12.1 Pfizer Company Information
  69. 8.12.2 Pfizer Business Overview
  70. 8.12.3 Pfizer Second-Generation Antipsychotics Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Pfizer Second-Generation Antipsychotics Product Portfolio
  72. 8.12.5 Pfizer Recent Developments
  73. 8.13 Hansoh Pharma
  74. 8.13.1 Hansoh Pharma Company Information
  75. 8.13.2 Hansoh Pharma Business Overview
  76. 8.13.3 Hansoh Pharma Second-Generation Antipsychotics Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Hansoh Pharma Second-Generation Antipsychotics Product Portfolio
  78. 8.13.5 Hansoh Pharma Recent Developments
  79. 8.14 Hisun Pharmaceutical
  80. 8.14.1 Hisun Pharmaceutical Company Information
  81. 8.14.2 Hisun Pharmaceutical Business Overview
  82. 8.14.3 Hisun Pharmaceutical Second-Generation Antipsychotics Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Hisun Pharmaceutical Second-Generation Antipsychotics Product Portfolio
  84. 8.14.5 Hisun Pharmaceutical Recent Developments
  85. 8.15 Nhwa Pharmaceutical
  86. 8.15.1 Nhwa Pharmaceutical Company Information
  87. 8.15.2 Nhwa Pharmaceutical Business Overview
  88. 8.15.3 Nhwa Pharmaceutical Second-Generation Antipsychotics Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Nhwa Pharmaceutical Second-Generation Antipsychotics Product Portfolio
  90. 8.15.5 Nhwa Pharmaceutical Recent Developments
  91. 8.16 AbbVie
  92. 8.16.1 AbbVie Company Information
  93. 8.16.2 AbbVie Business Overview
  94. 8.16.3 AbbVie Second-Generation Antipsychotics Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 AbbVie Second-Generation Antipsychotics Product Portfolio
  96. 8.16.5 AbbVie Recent Developments
  97. 8.17 Sumitomo Dainippon Pharma
  98. 8.17.1 Sumitomo Dainippon Pharma Company Information
  99. 8.17.2 Sumitomo Dainippon Pharma Business Overview
  100. 8.17.3 Sumitomo Dainippon Pharma Second-Generation Antipsychotics Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Sumitomo Dainippon Pharma Second-Generation Antipsychotics Product Portfolio
  102. 8.17.5 Sumitomo Dainippon Pharma Recent Developments
  103. 8.18 Otsuka Pharmaceutical
  104. 8.18.1 Otsuka Pharmaceutical Company Information
  105. 8.18.2 Otsuka Pharmaceutical Business Overview
  106. 8.18.3 Otsuka Pharmaceutical Second-Generation Antipsychotics Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Otsuka Pharmaceutical Second-Generation Antipsychotics Product Portfolio
  108. 8.18.5 Otsuka Pharmaceutical Recent Developments
  109. 8.19 Johnson And Johnson
  110. 8.19.1 Johnson And Johnson Company Information
  111. 8.19.2 Johnson And Johnson Business Overview
  112. 8.19.3 Johnson And Johnson Second-Generation Antipsychotics Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Johnson And Johnson Second-Generation Antipsychotics Product Portfolio
  114. 8.19.5 Johnson And Johnson Recent Developments
  115. 8.20 Ipsen
  116. 8.20.1 Ipsen Company Information
  117. 8.20.2 Ipsen Business Overview
  118. 8.20.3 Ipsen Second-Generation Antipsychotics Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Ipsen Second-Generation Antipsychotics Product Portfolio
  120. 8.20.5 Ipsen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Second-Generation Antipsychotics Value Chain Analysis
  2. 9.1.1 Second-Generation Antipsychotics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Second-Generation Antipsychotics Sales Mode & Process
  6. 9.2 Second-Generation Antipsychotics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Second-Generation Antipsychotics Distributors
  9. 9.2.3 Second-Generation Antipsychotics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst